In Depth 25 Sep 2024 How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s. September 25, 2024 - 9 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
In Depth 24 Sep 2024 New partnership model on the rise: how VCs are helping Pharma hunt for their next blockbuster Discover how the recent Pfizer-Flagship alliance model sets a trend in pharma-VC partnerships, fostering innovation in drug development. September 24, 2024 - 9 minutesmins - By Monica Karpinski Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market. July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 5 Jun 2024 Evolving standards of care: new treatments for cervical cancer New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients. June 5, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 8 Feb 2024 Could we see a new dawn for hair loss treatments? Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors. February 8, 2024 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2023 The big pharma race against deadly RSV steps up in 2023 GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition. December 21, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2023 Pfizer kicks $25M into CellCentric U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […] July 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Google Cloud adds AI solutions for drug discovery Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. The Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and […] May 19, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 18 Apr 2023 Gene therapy: a powerful tool for hemophilia B? The approval of HEMGENIX, the first-ever gene therapy for hemophilia B, by the U.S. Food and Drug Administration (FDA) followed by the European Commission, has been momentous in rare disease therapeutic research, paving the way for various gene therapies that are currently being studied. As we observed World Hemophilia Day on April 17, let us […] April 18, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction. “Pfizer is deploying its financial resources to […] March 14, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email